文献速递青光眼

晚期青光眼治疗研究:比较新诊断晚期青光眼初始药物治疗与初始小梁切除术的多中心随机对照试验——研究方案

Treatment of Advanced Glaucoma Study: a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma-study protocol.
PubMed 文献 · Br J Ophthalmol · 2017-10-26

晚期青光眼治疗研究是一项在英国27家医院眼科服务开展的前瞻性、实用性多中心随机对照试验,计划纳入440例新诊断晚期开角型青光眼患者,按1:1随机分配至药物治疗组或加强小梁切除术组,主要结局为24个月时视功能相关生活质量(NEI-VFQ-25),并评估成本效果。

要点

  • 研究比较新诊断晚期开角型青光眼初始药物与初始加强小梁切除术的临床与成本效果。
  • 主要结局为24个月时由NEI-VFQ-25测量的视功能相关生活质量。
  • 计划纳入440例按Hodapp-Parish-Anderson视野缺损分类为晚期开角型青光眼的患者。

核心结论

  • 该研究将报告药物治疗与加强小梁切除术在晚期青光眼患者中基于患者报告的健康与视功能、临床结局及2年每质量调整生命年增量成本的比较效果与成本效果。
  • 晚期青光眼治疗研究将是首个从晚期青光眼患者视角报告结局的随机对照试验。

研究设计与样本

  • 前瞻性、实用性多中心随机对照试验,在英国27家医院眼科服务开展。
  • 计划纳入440例按Hodapp-Parish-Anderson视野缺损分类为晚期开角型青光眼的患者。
  • 参与者按1:1随机分配至药物治疗或加强小梁切除术,按中心和双眼晚期病变情况进行最小化。

主要发现

  • 主要结局为24个月时由美国国家眼科研究所视功能问卷-25(NEI-VFQ-25)测量的视功能相关生活质量。
  • 次要结局包括通用EQ-5D-5L、健康效用指数-3、青光眼相关健康状况(青光眼效用指数)、患者体验、平均偏差值测量的视野、最小分辨角对数视力、眼压、不良事件、驾驶标准及盲证资格。
  • 将估算基于EQ-5D-5L和青光眼画像工具的每质量调整生命年增量成本。
  • 研究将在2年时报告患者报告的健康与视功能、临床结局及每质量调整生命年增量成本方面的比较效果与成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Presentation with advanced glaucoma is the major risk factor for lifetime blindness. Effective intervention at diagnosis is expected to minimise risk of further visual loss in this group of patients. AIM: To compare clinical and cost-effectiveness of primary medical management compared with primary surgery for people presenting with advanced open-angle glaucoma (OAG). METHODS: Design: A prospective, pragmatic multicentre randomised controlled trial (RCT). SETTING: Twenty-seven UK hospital eye services. PARTICIPANTS: Four hundred and forty patients presenting with advanced OAG, according to the Hodapp-Parish-Anderson classification of visual field loss. INTERVENTION: Participants will be randomised to medical treatment or augmented trabeculectomy (1:1 allocation minimised by centre and presence of advanced disease in both eyes). MAIN OUTCOME MEASURES: The primary outcome is vision-related quality of life measured by the National Eye Institute-Visual Function Questionnaire-25 at 24 months. Secondary outcomes include generic EQ-5D-5L, Health Utility Index-3 and glaucoma-related health status (Glaucoma Utility Index), patient experience, visual field measured by mean deviation value, logarithm of the mean angle of resolution visual acuity, intraocular pressure, adverse events, standards for driving and eligibility for blind certification. Incremental cost per quality-adjusted life-year (QALY) based on EQ-5D-5L and glaucoma profile instrument will be estimated. RESULTS: The study will report the comparative effectiveness and cost-effectiveness of medical treatment against augmented trabeculectomy in patients presenting with advanced glaucoma in terms of patient-reported health and visual function, clinical outcomes and incremental cost per QALY at 2 years. CONCLUSIONS: Treatment of Advanced Glaucoma Study will be the first RCT reporting outcomes from the perspective of those with advanced glaucoma. TRIAL REGISTRATION NUMBER: ISRCTN56878850, Pre-results.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. King AJ, Fernie G, Azuara-Blanco A, et al. Treatment of Advanced Glaucoma Study: a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma-study protocol. Br J Ophthalmol. 2017. PMID: 29074496. doi:10.1136/bjophthalmol-2017-310902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。